Massive Genetic Study Reveals New Molecular Targets for Bronchiectasis Across Ancestries

Bronchiectasis, a chronic and often debilitating airway disease in which the bronchial tubes become permanently widened, scarred, and prone to recurrent infection, has long remained in the shadow of its better-known respiratory cousins such as COPD and asthma. Now, a large-scale genetic investigation published in the Journal of Translational Medicine has delivered one of the most comprehensive views to date of the disease’s inherited underpinnings, scanning the genomes of more than 16,000 patients and nearly two million healthy controls across European and East Asian populations. The study, led by Ke Miao and colleagues at Peking University together with collaborators at Imperial College London, combines classic genome-wide association analysis with a battery of modern multi-omics tools to move beyond statistical associations and toward biologically actionable molecular targets.

The scale of the underlying data is itself noteworthy. The team conducted ancestry-specific meta-analyses of genome-wide association studies, or GWAS, in Europeans and East Asians separately, and then pooled the results in a joint trans-ancestry meta-analysis encompassing 16,030 bronchiectasis cases and 1,841,141 controls. This design matters because genetic architectures can differ subtly between populations, and combining ancestries increases both statistical power and the chances of detecting variants that are rare or population-specific. The ancestry-specific analyses identified five bronchiectasis lead loci in Europeans and one in East Asians, while the trans-ancestry analysis converged on five lead signals, the strongest of which was a variant known as rs28929474, annotated to the gene SERPINA1.

That top hit is biologically compelling. SERPINA1 encodes alpha-1 antitrypsin, a protease inhibitor whose deficiency is already a well-established cause of both emphysema and bronchiectasis. The fact that the strongest cross-ancestry signal lands squarely on this gene provides a satisfying validation of the study’s methodology: the analysis is not merely generating statistical noise but recovering biology that clinicians already recognize, while simultaneously extending it to new candidates. It also underscores the value of including diverse populations, since signals that might be diluted or absent in one ancestry can emerge clearly when data from multiple ancestries are integrated.

Identifying lead variants is only the first step in modern disease genetics, because a single genomic region can contain dozens of correlated variants that travel together through inheritance, a phenomenon known as linkage disequilibrium. To disentangle which variants are most likely to be the true causal drivers, the researchers performed statistical fine-mapping, a computational approach that weighs each candidate variant’s association strength and correlation structure to produce credible sets of plausible culprits. This procedure yielded two credible sets in the European analysis and three in the trans-ancestry analysis, narrowing the field of candidate causal variants considerably and providing a more precise starting point for functional follow-up.

Perhaps the most innovative layer of the study is its use of proteome-wide Mendelian randomization based on cis-protein quantitative trait loci, or cis-pQTLs. Mendelian randomization exploits naturally occurring genetic variants as instruments to test whether a causal relationship exists between an exposure, in this case the circulating level of a specific protein, and a disease outcome. Because genetic variants are randomly allocated at conception, this approach is largely immune to the confounding and reverse causation that plague observational epidemiology. By restricting instruments to variants near the gene encoding each protein, the researchers reduced the risk of pleiotropic artifacts. In the European data, this analysis, combined with colocalization tests that verify whether the same variant drives both protein levels and disease risk, prioritized AIF1 and WWP2 as candidate proteins for bronchiectasis. The corresponding East Asian analyses nominated HSPA1A and DXO.

These protein candidates span intriguing biology. AIF1, also known as allograft inflammatory factor 1, is involved in immune cell activation and inflammatory signaling, processes central to the chronic neutrophilic inflammation that characterizes bronchiectatic airways. WWP2 is an E3 ubiquitin ligase with roles in protein degradation and developmental signaling pathways, including those governing airway epithelial biology. HSPA1A encodes a heat shock protein that orchestrates cellular stress responses, while DXO participates in RNA processing and quality control. That different ancestries surfaced different candidate proteins is not necessarily a weakness of the study; rather, it may reflect genuine population-level differences in disease mechanisms, differing allele frequencies, or differences in the protein quantitative trait loci resources available for each group. Each candidate now represents a hypothesis that can be tested experimentally in cellular and animal models of airway disease.

The team also applied transcriptome-wide association studies, or TWAS, which ask whether genetically predicted expression of a gene in a specific tissue, here the lung, is associated with disease risk. Integrated with colocalization analysis to ensure the expression signal and the disease signal share the same underlying variant, the lung TWAS in Europeans prioritized CHP2 and FUBP1. CHP2 is a calcineurin homologous protein implicated in ion transport and cell proliferation pathways, while FUBP1 is a far upstream element binding protein that regulates transcription and, notably, has been linked to the expression of CFTR, the chloride channel whose mutations cause cystic fibrosis, itself the classic cause of bronchiectasis. This convergence of transcriptomic and proteomic evidence with known airway biology strengthens confidence that the prioritized targets are not statistical artifacts.

Beyond bronchiectasis in isolation, the study tackled a question of considerable clinical importance: why do bronchiectasis, COPD, asthma, and chronic bronchitis so frequently coexist in the same patients? The researchers quantified genetic correlation between bronchiectasis and these overlapping conditions, then performed cross-disease pleiotropic analyses to identify variants influencing more than one disease. This effort highlighted shared signals at SERPINA1, SMAD3, CFTR, and PHTF1, with additional support for SMAD3 coming from blood cis-eQTL-based Mendelian randomization and colocalization. SMAD3 is a central transducer of the TGF-beta signaling pathway, which regulates airway remodeling and fibrosis, and variants in SMAD3 are known to contribute to thoracic aortic disease with features overlapping connective tissue disorders. CFTR, as the cystic fibrosis gene, needs little introduction in this context, and its appearance among the shared signals reinforces the idea that impaired airway surface hydration and mucociliary clearance form a common mechanistic thread linking several chronic airway diseases.

The implications for drug development are tangible. Bronchiectasis currently lacks mechanism-informed therapies; management relies largely on airway clearance techniques, antibiotics for infective exacerbations, and treatment of underlying causes where they can be identified. By prioritizing proteins and genes whose genetically determined levels or expression influence disease risk, the study provides a shortlist of targets that pass some of the most stringent causal filters available in human genetics. Drugs aimed at proteins with human genetic evidence of disease relevance have historically shown higher success rates in clinical trials, and the multi-omics triangulation used here, spanning GWAS, fine-mapping, pQTL-based and eQTL-based Mendelian randomization, TWAS, and colocalization, is precisely the kind of evidence stack that pharmaceutical target selection increasingly demands.

Caveats remain, as they must in any genetics-first study. The analyses relied on summary-level data from previously generated studies, which means individual-level covariates, environmental exposures, and disease subphenotypes could not be modeled directly. Protein and expression quantitative trait loci resources differ in depth between ancestries, and the candidate targets nominated in East Asians and Europeans will require replication in additional cohorts and functional validation before they inform clinical practice. Nevertheless, the study marks a clear advance: it refines the cross-ancestry genetic architecture of bronchiectasis, confirms the centrality of protease-antiprotease imbalance through SERPINA1, and elevates a set of new molecular suspects, from AIF1 and WWP2 to CHP2 and FUBP1, into the spotlight of translational respiratory research. For a disease that has waited decades for precision-medicine attention, the genetic map is finally beginning to fill in.

Subject of Research: Cross-ancestry genetic architecture of bronchiectasis and multi-omics prioritization of candidate molecular drug targets

Article Title: Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets

Article References: Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets. (n.d.). https://doi.org/10.1186/s12967-026-09081-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09081-2

Keywords: bronchiectasis, GWAS, meta-analysis, Mendelian randomization, SERPINA1, pQTL, TWAS, colocalization, COPD, asthma, chronic bronchitis, drug targets